IDE196-002 https://www.nct-dresden.de/en/trials/900-000002435 https://www.nct-dresden.de/@@site-logo/logo-nct.svg IDE196-002 Category Skin tumors Subcategory Other dermatological tumors Trial Type First-Line-Therapy (Metastatic Disease/Hematology) Description for experts IDE196 (Darovasertib) in combination with Crizitinib versus Investigator´s Choice of treatment as first-line therapy in HLA-A2 negative metastatic uveal melanoma Description for laymen
